The healthcare and pharmaceutical sector saw robust deal activity and strategic expansion. Jazz Pharmaceuticals and Lisata Therapeutics announced major acquisitions, while Gujarat Themis Biosyn completed a cross-border deal in Japan. Meanwhile, Cardinal Health outlined strong long-term EPS targets and China set ambitious growth plans for innovative drugs.
01Company specific
Cardinal Health Outlines Growth in Specialty and At-Home Investments
Anchoring growth in specialty MSOs and automated small-parcel at-home logistics pivots pharmaceutical wholesalers from low-margin volume distribution toward defensible, higher-margin care management.
Cardinal Health expects fiscal 2027 adjusted -per-share to grow 13% to 15% as operating momentum normalizes following an outsized fiscal 2026. CEO Jason Hollar outlined the at recent investor conferences, pointing to operating-income expansion across the company's three reporting segments and five operating businesses. Fiscal 2026 results benefited from broad strength, including a 25% surge in the specialty business, higher healthcare utilization, and new customer onboarding. Growth in fiscal 2027 will rely on lower interest expense, a slightly higher tax rate, and $1 billion in planned share repurchases. The company is actively expanding its footprint in specialty platforms like , urology, and gastroenterology through bolt-on and managed-services organizations. At the same time, Cardinal Health is building out automated small-parcel distribution centers for higher-value at-home products, anchored by closed deals like Strive Medical and pending transactions such as AdaptHealth's diabetes business.
Walmart Partners With SCAN Health Plan to Launch Medicare Advantage Plans
Combining retail transaction data with health plan benefits leverages everyday consumer purchasing history to lower care costs and lock in long-term pharmacy footprint dominance.
Walmart and SCAN Health Plan announced a partnership on Wednesday to launch co-branded Advantage plans across two states, targeting a pool of more than two million Medicare enrollees. The offering integrates pharmacy, vision, food assistance, and over-the-counter benefits with Walmart's health ecosystem, pending regulatory approval. Members gain access to Everyday Health Signals, an platform that generates personalized nutrition and wellness from user shopping preferences and stated health goals. SCAN operates a health plan serving nearly 460,000 members across 33 counties, while Walmart brings a decade of in-store insurance experience and its licensed agency established in 2020. Financial terms of the collaboration were not disclosed.
Diluting legacy shareholders to a tiny fraction trades an existing oncology pipeline entirely for a fully funded, clinical-stage cardioendocrine portfolio.
Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction and secured a concurrent $225 million private placement to pivot its pipeline toward cardioendocrine diseases. Marea was exchanged for Lisata common stock and Series C non-voting convertible preferred shares. Pre-transaction Marea shareholders will own approximately 59.54% of the combined company, private-placement investors will hold 38.07%, and pre- Lisata shareholders will retain 2.39%. The combined entity will prioritize Marea lead programs MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly, with topline Phase 2 results expected in the fourth quarter of 2027. The private placement proceeds are expected to fund operations into 2028.
Jazz Pharmaceuticals acquires epilepsy assets in $820 million transaction
Absorbing up-front research costs to secure designated rare-disease assets tests whether commercial scale in specialized markets can offset the GAAP earnings drag of clinical-stage acquisitions.
Jazz Pharmaceuticals acquired privately held Actio Biosciences for $820 million upfront, adding the clinical-stage epilepsy drug ABS-1230 to its rare disease pipeline. The transaction closes as Jazz carries $4.4 billion in long-term and $2.2 billion in cash, equivalents, and investments following the repayment of $1.0 billion in exchangeable notes. ABS-1230 targets KCNT1-related epilepsy and holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations. The deal follows a second quarter where rose 16 percent year over year to $1.2 billion, prompting management to raise full-year 2026 revenue to a range of $4.6 billion to $4.75 billion. Past have weighed on GAAP results, including a $905.4 million in-process research and development charge tied to the Chimerix acquisition that resulted in a second-quarter 2025 loss of $11.74 per share.
Upperton Receives MHRA Approval for Nottingham Sterile Manufacturing Facility
Securing Annex-compliant sterile capacity alongside existing development capabilities lets contract manufacturers capture higher-margin early-phase clinical business that previously required splitting supply chains across multiple vendors.
Upperton secured regulatory approval from the Medicines and Healthcare products Regulatory Agency for its new sterile manufacturing facility at Trent Gateway in Nottingham. The 7,000 sq. ft facility received a variation to the company's existing Manufacturing and Importation Authorisation for Investigational Medicinal Products licence, bringing the site into scope for Good Manufacturing Practice production. This authorization allows the contract development and manufacturing organization to begin producing sterile investigational medicinal products for early-phase . The facility features Grade A isolator environments, vapor hydrogen peroxide bio-decontamination, and terminal sterilisation capabilities designed around revised EU GMP Annex 1 requirements. Situated alongside the company's existing 50,000 sq. ft development site, the new infrastructure completes an integrated offering that spans formulation development, analytical testing, and both sterile and non-sterile clinical manufacture.
China Sets Global Biopharma Expansion Goals in New Five-Year Plan
Mandated R&D spending thresholds and first-in-class quotas pivot Chinese drugmakers from low-cost manufacturing competitors into direct, state-backed rivals for global biotech market share.
China released its 15th Five-Year Plan for the pharmaceutical industry, targeting operating above CNY 3.5 trillion by 2030. The joint directive from the Ministry of Industry and Information Technology, the National Development and Reform Commission, and eight other agencies sets a 20 percent average annual growth rate for innovative drugs. The policy shifts state backing from scale manufacturing to high-end innovation, mandating that first-in-class drugs account for more than 25 percent of the global total by the end of the decade. Listed drugmakers must maintain an average R&D intensity of at least 10 percent annually, while the sector aims to produce at least five products with global annual sales exceeding $1 billion. The roadmap also establishes 50 pharmaceutical enterprises with annual revenue above CNY 10 billion and 20 industrial parks at the 100-billion-yuan scale. Strategic investments will target , quantum computing, brain-computer interfaces, and cell therapy as priority breakthroughs.
Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan
Funding fermentation capacity through heavy leverage tests whether high-margin API manufacturing can service substantial debt before new regulatory approvals yield incremental revenue.
Gujarat Themis Biosyn Limited completed its of MicroBiopharm Japan Co., Ltd. for a total consideration of JPY 21.5 billion, or roughly Rs 1,300 crore. The transaction was executed through Themis Biosyn Japan Limited, a wholly owned subsidiary funded by Rs 475 crore in and Rs 745 crore in loans, backed by an arranged loan facility of up to Rs 800 crore. The purchase brings three GMP-compliant manufacturing plants, precision fermentation platforms, and established client relationships into the Indian API manufacturer's . Management structured the buyout to be accretive while expanding non-current liabilities from Rs 32.37 crore to Rs 136.51 crore in FY26 to finance the growth strategy.
Aggressive capital deployment across biotech M&A and global manufacturing expansion reflects high confidence in commercial pipelines. However, whether emerging platforms and international acquisitions can deliver expected returns under shifting regulatory and market conditions unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.